You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 11,752,190

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,752,190

Title:	Modulators of complement activity
Abstract:	The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.
Inventor(s):	Steven James DeMarco, Michelle Denise Hoarty, Grace Victoria Parker, Alonso Ricardo, Sylvia Tobe, Douglas A. Treco
Assignee:	Ucb Holdings Inc
Application Number:	US17/065,560
Patent Claims:	1. A pharmaceutical composition comprising a C5 inhibitor polypeptide comprising the core amino acid sequence of SEQ ID NO: 1; a salt; and a buffering agent. 2. The pharmaceutical composition of claim 1, wherein the salt comprises sodium chloride. 3. The pharmaceutical composition of claim 1, wherein the salt is present at a concentration of from about 25 mM to about 100 mM. 4. The pharmaceutical composition of claim 1, wherein the buffering agent comprises sodium phosphate. 5. The pharmaceutical composition of claim 1, wherein the buffering agent is present at a concentration of from about 10 mM to about 100 mM. 6. The pharmaceutical composition of claim 1 comprising a pH of from about 6.5 to 7.5. 7. The pharmaceutical composition of claim 1, wherein the polypeptide is present at a concentration of from about 1 mg/mL to about 400 mg/mL. 8. The pharmaceutical composition of claim 7, wherein the polypeptide binds to C5 with an equilibrium dissociation constant (KD) of from about 0.1 nM to about 1 nM. 9. The pharmaceutical composition of claim 8, wherein the polypeptide blocks production of C5a following activation of the alternative pathway of complement activation. 10. The pharmaceutical composition of claim 8, wherein the polypeptide blocks formation of the membrane attack complex (MAC) following activation of the classical pathway, alternative pathway, or lectin pathway of complement activation. 11. The pharmaceutical composition of claim 1, wherein the polypeptide is present at a concentration of about 40 mg/mL. 12. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises about 75.7 mM sodium chloride. 13. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises about 50 mM sodium phosphate. 14. A method of treating a complement-related disorder in a subject, the method comprising providing the pharmaceutical composition of claim 1 to the subject. 15. The method of claim 14, wherein the pharmaceutical composition is administered subcutaneously (SC) or intravenously (IV) to the subject. 16. The method of claim 14, wherein the subject is vaccinated against Neisseria meningitides. 17. The method of claim 14, wherein the subject is coadministered eculizumab, cyclosporin, and/or an antibiotic. 18. An auto-injector device comprising the pharmaceutical composition of claim 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.